Contact our responsive and friendly client services team any time.
(03) 9028 2888
clients@freshequities.com
Investor presentation - Invion Limited
Health
Invion Limited (IVX) is a clinical-stage drug development company in the biotechnology and pharmaceutical industry in Australia. IVX has three key development programs: INV102 for inflammatory respiratory disease; INV104, a leukotriene receptor antagonist; and, INV103, a modified, naturally occurring human protein. Former Names Cbio Limited (CBZ), 04/09/2012.
Read moreMarket Cap
Price at Close
4w avg. Volume
4w avg. Turnover
announcement | t+2 movement | date |
---|---|---|
| - | 17 Jan 2021 |
| - | 17 Jan 2021 |
| 0.00% | 12 Jan 2021 |
| +10.00% | 23 Dec 2020 |
| +10.00% | 23 Dec 2020 |
| +10.00% | 23 Dec 2020 |
| 0.00% | 14 Dec 2020 |
| 0.00% | 14 Dec 2020 |
| 0.00% | 14 Dec 2020 |
| 0.00% | 14 Dec 2020 |
Current Price
52WK HIGH
52WK LOW
1YR RETURN
1YR RETURN VS. SECTOR
90 DAY RETURN
ASX RANK
/2,047
SECTOR RANK
/168
SHARES OUTSTANDING
Health
Invion Limited (IVX) is a clinical-stage drug development company in the biotechnology and pharmaceutical industry in Australia. IVX has three key development programs: INV102 for inflammatory respiratory disease; INV104, a leukotriene receptor antagonist; and, INV103, a modified, naturally occurring human protein. Former Names Cbio Limited (CBZ), 04/09/2012.
Read moreMarket Cap
Price at Close
4w avg. Volume
4w avg. Turnover
ASX:IVX is not raising right now
Want to invest?
(03) 9028 2888
clients@freshequities.com
Level 7, 388 Bourke St
Melbourne VIC 3000
Australia